ArticleFrontiers in oncology2025
Development and external validation of a prognostic nomogram for event-free survival in resectable non-small cell lung cancer after neoadjuvant chemoimmunotherapy.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Combining multiple prognostic factors can enhance risk assessment for resected non-small cell lung cancer (NSCLC). Our aim was to evaluate the prognostic significance of ypT staging, ypN staging, major pathologic response (MPR) and pathology response in lymph node, and to develop a combined prognostic model to predicting event-free survival in resectable NSCLC patients after neoadjuvant chemoimmunotherapy (NCI). Methods and results: Two independent cohorts (derivation, n=208; external validation, n=91) were utilized. Pathologic assessment and ypTNM staging followed recommendations from the International Association for the Study of Lung Cancer (IASLC) and the 8th edition AJCC TNM classification. The evaluation of lymph node is documented according to IASLC recommendations, and the mean metastatic tumor size (MTS) in lymph node was evaluated in each case. MPR was defined as ≤10% residual visible tumor in the tumor bed. The survival endpoint was event-free survival (EFS). Univariate and multivariate survival analyses identified nonMPR (HR, 2.860; 95% CI, 1.245-6.567, p=0.013), ypT3/4 (HR, 3.987; 95% CI, 1.496-10.629, p=0.006), and MTS (MTS ≤ 4.5mm vs negative; HR, 4.059; 95% CI, 1.558-10.571, p=0.004; MTS>4.5mm vs negative; HR, 6.871; 95% CI, 1.713-27.564, p=0.007) were independent adverse prognostic factors in the derivation cohort. We built a nomogram model including ypT stage, MPR and pathology response in lymph node to predict EFS, demonstrating high efficacy in both derivation (the Area Under Curve, AUC = 0.77) and external validation cohorts (AUC = 0.72). The Risk Stratification System showed that the EFS of low-risk patients was considerably better than that of high-risk patients (P < 0.0001). Conclusions: Prognostic model integrating ypT staging, MPR and the mean MTS improves EFS prediction for NSCLC following NCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.